The startup has developed a compact, portable cancer detection system that utilizes automated diagnostics to identify cancer biomarkers with 85% sensitivity and 91% specificity in just 30 minutes. This technology eliminates the need for third-party laboratory processing, reducing human error and accelerating the turnaround time for test results, enabling earlier and more effective cancer treatment.
Funding
$350K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer detection methods often require sending samples to third-party laboratories, leading to potential delays and increased risk of human error in processing, ultimately delaying diagnosis and treatment. Existing diagnostic processes can also be time-consuming and costly.
Solution
Harae DX offers a compact, portable, and automated cancer detection system designed for rapid and accurate identification of cancer biomarkers. The system eliminates the need for external laboratory processing by providing a complete, automated solution at the point of care. Using a proprietary, patented technology platform, the system aims to reduce human error and accelerate the turnaround time for test results, enabling earlier and more effective cancer treatment. The system reports 85% sensitivity and 91% specificity in detecting cancer biomarkers within 30 minutes.
Target Audience
The primary target audience includes healthcare providers, oncologists, and diagnostic centers seeking to improve the speed and accuracy of cancer detection.
Features
- Compact and portable design for point-of-care testing
- Automated diagnostics to minimize human error
- Rapid results in 30 minutes per test
- High sensitivity (85%) and specificity (91%) in biomarker detection
- Proprietary, patented technology platform
- Eliminates the need for third-party laboratory processing